Isolation and Characterization of Hermetia Illucens Larval Protein for the Assessment of Inhibitory Activity against MCF7 and HeLa cell Lines

Abstract

Cancer has a major impact on society having the highest morbidity and mortality rate. Approximately 70% of deaths are predominantly caused due to cancer and it prevails in low and middle-income countries, as they are unaware of the signs and symptoms, treatment methods, non-availability of cancer drugs and the incurrence of huge economic burden on the family. As per the literature, the chemotherapeutic drug has numerous side effects and occasionally it may lead to death. Based on these inferences, there is a requirement to identify therapeutic peptides that are more effective for cancer treatment with less toxic effects on the body. Peptides have a great advantage to fight against the disease efficiently. Several flies have anticancer, antibacterial, antifungal and antioxidant properties that help to control disease and inhibit cancer progression. In the present research, we have utilized Hermetia illucens has great anticancer peptides that can control cancer growth. In the current research, we utilized crude protein extraction from Hermetia illucens larvae, to discover the inhibitory activity against MCF7 and HeLa cell lines. by adopting the MTT assay method, along with reference drug Camptothecin. Bradford assay results helped to identify that 23.5μg/ml concentration of protein is present in the crude sample. Flow cytometry was used to calculate the % of cell violations and IC50 values were observed in HeLa (19.88±50.3μg/mL) and MCF7 (224.68±50.3μg/mL) cells. Cell cycle inhibition was observed in HeLa cells of G1 (57.3±1.2) and, S (19.8±1.3) phase of dose-dependent with the significance of (P<0.05). Hermetia illucens crude protein has significant inhibition with HeLa cells that have the best anti-cancer proteins in human cervical carcinoma cells.